MarketFriction

Ortin Global Ltd

NSE ORTINGLOBE · BSE 539287 · Pharmaceuticals
₹14.52 +1.40%
NSE close2026-10-01
52 week range10.66 - 21.30
Market cap₹11.9 Cr.
GSM Price band 5% Delivery 48.7%

Price

Drag to pan, scroll or pinch to zoom. Ruler (or Shift + drag) measures a move.Dashed lines: 52 week high and low. Prices adjusted for splits and bonuses.

Financials

Standalone, Rs crore
Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales0.270.140.300.210.050.030.090.080.010.010.300.01
Expenses1.172.743.350.310.500.160.250.240.510.060.310.34
Operating Profit-0.90-2.60-3.05-0.10-0.45-0.13-0.16-0.16-0.50-0.05-0.01-0.33
OPM %-333.33%-1,857.14%-1,016.67%-47.62%-900.00%-433.33%-177.78%-200.00%-5,000.00%-500.00%-3.33%-3,300.00%
Other Income0.000.000.000.000.000.020.000.000.000.000.000.00
Interest0.150.140.080.000.02-0.010.000.000.000.000.000.00
Depreciation0.060.060.050.000.000.000.000.000.000.000.000.00
Profit before tax-1.11-2.80-3.18-0.10-0.47-0.10-0.16-0.16-0.50-0.05-0.01-0.33
Tax %1.80%-0.71%30.19%0.00%0.00%10.00%0.00%6.25%0.00%0.00%0.00%0.00%
Net Profit-1.12-2.79-4.14-0.10-0.47-0.11-0.16-0.18-0.50-0.05-0.01-0.34
EPS in Rs-1.38-3.43-5.09-0.12-0.58-0.14-0.20-0.22-0.61-0.06-0.01-0.42
Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales62.7261.5779.63167.51197.368.168.236.002.010.340.100.33
Expenses56.8356.1274.22160.83191.666.927.855.476.401.231.131.22
Operating Profit5.895.455.416.685.701.240.380.53-4.39-0.89-1.03-0.89
OPM %9.39%8.85%6.79%3.99%2.89%15.20%4.62%8.83%-218.41%-261.76%-1,030.00%-269.70%
Other Income0.570.320.450.130.180.050.190.01-1.980.060.310.00
Interest3.422.943.493.223.210.870.810.400.480.000.000.00
Depreciation1.651.701.691.751.960.290.290.250.230.010.000.00
Profit before tax1.391.130.681.840.710.13-0.53-0.11-7.08-0.84-0.72-0.89
Tax %41.01%55.75%0.00%30.43%181.69%-623.08%-24.53%-18.18%13.56%1.19%2.78%
Net Profit0.830.500.681.28-0.560.95-0.40-0.09-8.04-0.85-0.74-0.90
EPS in Rs0.490.300.400.76-0.331.17-0.49-0.11-9.89-1.05-0.91-1.10
Dividend Payout %0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%
10 Years5 Years3 YearsTTM1 YearLast Year
Compounded Sales Growth-47%-59%-74%32%
Compounded Profit Growth%%%4%
Stock Price CAGR-2%-11%-8%31%
Return on Equity-4%-26%-73%-48%
Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital16.9416.9416.9416.9416.9416.948.138.138.138.138.138.13
Reserves5.506.336.467.148.156.883.222.832.73-5.31-6.15-6.89
Borrowings20.9620.8517.3417.3419.4719.576.946.146.451.800.251.01
Other Liabilities23.8721.2220.7932.2460.5373.132.973.613.892.051.552.40
Total Liabilities67.2765.3461.5373.66105.09116.5221.2620.7121.206.673.784.65
Fixed Assets21.8321.6320.6920.0321.2922.4514.3814.2113.960.010.000.01
CWIP0.000.000.350.400.530.430.430.430.430.000.000.00
Investments0.030.030.070.080.080.070.000.000.000.000.000.00
Other Assets45.4143.6840.4253.1583.1993.576.456.076.816.663.784.64
Total Assets67.2765.3461.5373.66105.09116.5221.2620.7121.206.673.784.65
Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from Operating Activity-1.380.521.941.566.523.3018.032.15-0.25-4.79-0.41-0.56
Cash from Investing Activity0.22-0.86-1.26-0.90-3.27-3.090.07-0.130.0112.000.000.04
Cash from Financing Activity1.730.27-0.820.07-2.89-1.33-9.86-0.480.90-3.490.330.75
Net Cash Flow0.58-0.07-0.140.730.37-1.128.251.550.663.72-0.090.23
Free Cash Flow-1.38-0.920.830.773.380.2818.032.02-0.247.21-0.41-0.52
CFO/OP-14%17%47%40%104%72%1,454%566%-47%80%46%54%
Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days103.7753.1390.35100.1582.4368.71174.90143.69208.05321.42279.12730.00
Inventory Days192.30148.72158.21152.21100.07117.80169.10136.29279.944.9234.760.00
Days Payable151.0924.82108.10143.09145.12155.80123.8261.88166.897.8769.52
Cash Conversion Cycle144.97177.04140.45109.2837.3830.70220.17218.10321.10318.47244.36730.00
Working Capital Days29.0016.2437.2941.4816.8211.24-87.22-109.10-43.19357.741,524.412,993.00
ROCE %12.07%10.92%9.57%9.44%11.77%8.94%3.24%1.58%1.80%-40.58%-25.11%-33.93%
Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Promoters7.37%7.36%1.23%1.23%1.23%1.23%1.23%1.23%1.23%1.23%1.23%1.23%
FIIs0.00%0.00%0.00%6.25%6.25%6.25%6.53%6.53%1.68%1.68%1.68%1.80%
Public92.64%92.64%98.76%92.53%92.52%92.52%92.24%92.24%97.08%97.09%97.10%96.96%
No. of Shareholders11,83612,31412,19211,95212,16512,09412,14412,03412,06011,83411,45211,383

Fundamentals

Market Cap₹ 11.9 Cr.
Current Price₹ 14.6
Book Value₹ 1.52
ROCE-33.9 %
ROE-48.4 %
Dividend Yield0.00 %
Face Value₹ 10.0
Compounded Sales Growth (TTM)32%
Compounded Profit Growth (TTM)4%
Standalone figures.
Valuation
Market capRs 12 Cr
Enterprise valueRs 12 Cr
Price to book9.52x
Price to sales35.78x
EV / sales36.99x
Earnings yield-7.62%
P/B, 3-year average5.99x
P/B, 5-year average4.19x
Profitability
Operating margin (excl. other income)-1030.00%
Operating margin (incl. other income)-720.00%
EBITDA margin-269.70%
Pre-tax margin-269.70%
Net profit margin-272.73%
Net margin, latest quarter-3400.00%
ROE-45.96%
ROCE-32.14%
ROA-17.56%
ROE, 3-year average-66.31%
ROCE, 3-year average-38.95%
ROA, 3-year average-30.51%
ROE, 5-year average-40.67%
ROCE, 5-year average-22.72%
ROA, 5-year average-18.77%
ROIC (approx.)-55.78%
Tax rate-2.78%
Other income / net worth25.00%
Growth
Sales growth (latest year)-70.59%
Sales CAGR, 3 years-74.46%
Sales CAGR, 5 years-58.54%
Sales growth QoQ-96.67%
Sales growth YoY (latest quarter)-87.50%
Per share
EPS (TTM)Rs -1.11
EPS (latest year)Rs -0.91
EPS (latest quarter)Rs -0.42
EPS, 3-year averageRs -3.95
EPS, 5-year averageRs -2.49
Book value per shareRs 1.52
Sales per shareRs 0.41
Cash flow per shareRs -0.69
Free cash flow per shareRs -0.64
Efficiency
Asset turnover0.02x
Fixed asset turnover10.00x
Debtor days730 days
Debtors turnover0.50x
Creditor days70 days
Cash conversion cycle730 days
Working capital days2993 days
Leverage
Total debtRs 1 Cr
Cash and bankRs 1 Cr
Net debtRs 0 Cr
Debt to equity0.81x
Owners' fund to total sources26.67%
Debt to assets21.72%
Cash flow
Cash from Operating Activity (latest year)Rs -1 Cr
Cash from Investing Activity (latest year)Rs 0 Cr
Cash from Financing Activity (latest year)Rs 1 Cr
Net Cash Flow (latest year)Rs 0 Cr
Free cash flow (latest year)Rs -1 Cr
FCFE (approx.: FCF + change in debt)Rs 0 Cr
Statement figures
Net sales (TTM)Rs 0 Cr
Net sales (latest year)Rs 0 Cr
Sales (latest quarter)Rs 0 Cr
Operating profit excl. other income (latest year)Rs -1 Cr
Operating profit (latest quarter)Rs -0 Cr
Other income (TTM)Rs 0 Cr
EBITDA (TTM)Rs -1 Cr
PBDT (TTM)Rs -1 Cr
Profit before tax (TTM)Rs -1 Cr
Tax (latest year)Rs 0 Cr
Net profit (TTM)Rs -1 Cr
Net profit (latest year)Rs -1 Cr
Net profit (latest quarter)Rs -0 Cr
Cost of goods sold (latest year)Rs 0 Cr
Total expenditure (latest year)Rs 1 Cr
Total income (latest year)Rs 0 Cr
Share capitalRs 8 Cr
ReservesRs -7 Cr
Shareholders' fundsRs 1 Cr
Total assetsRs 5 Cr
Net blockRs 0 Cr
ReceivablesRs 0 Cr
Other liabilitiesRs 2 Cr
Shares outstanding (crore)0.81
Ownership
Promoter holding1.23% (+0.00 in a year)
Computed by MarketFriction from the standalone statements. Returns use average balances.
P/B 9.52 is at the 96th percentile (median 1.48).
Monthly. Market cap from split-adjusted price; profit and book value as reported by that month. A low percentile means cheap versus its own history, not cheap versus peers.
PeriodORTINGLOBENifty 50Difference
1 week-1.6%-2.8% +1.2 pts
1 month-8.4%-6.8% -1.7 pts
3 months-10.6%-7.6% -3.0 pts
6 months+7.1%+0.4% +6.7 pts
1 year+25.7%-9.9% +35.6 pts
2 years-31.3%-13.6% -17.8 pts
3 years-24.0%+14.2% -38.2 pts
5 years-45.1%+27.9% -73.0 pts

Red flags

F-score 3 of 8
explainReceivables outrunning sales Receivables grew -23% vs sales -71% in 2026
lookRepeated losses Net loss in each of the last two years
lookOn NSE surveillance On NSE surveillance: GSM
Checks on the latest reported years: cash vs profit, accruals, receivables and inventory vs sales, dilution, debt, interest cover, equity, other income, losses, and auditor, top-management, insolvency and regulator filings in the last 12 months. A flag asks for an explanation; it is not a verdict.

Latest quarter

Jun 2026
Sales ₹0 Cr -87.5% vs Jun 2025. Net loss ₹0 Cr.

Activity

Compare
CompanyMcap (Cr)P/EROCE
Sun Pharmaceutical Industries Ltd447,47635.420.5 %
Divis Laboratories Ltd250,36384.022.0 %
Torrent Pharmaceuticals Ltd186,15283.415.2 %
Zydus Lifesciences Ltd119,75024.621.1 %
Cipla Ltd111,43031.115.5 %
Laurus Labs Ltd106,92897.817.8 %
Mankind Pharma Ltd105,12049.313.5 %
Dr Reddys Laboratories Ltd104,49432.413.0 %
Aurobindo Pharma Ltd97,68225.812.9 %
Lupin Ltd93,84015.829.9 %
Glenmark Pharmaceuticals Ltd68,90522.139.8 %
Alkem Laboratories Ltd62,77227.621.2 %
Biocon Ltd61,43984.53.61 %
Abbott India Ltd57,94935.944.8 %
Gland Pharma Ltd49,33343.115.1 %
No bulk or block deals on record.
Ex-dateActionFactor
2023-09-22Annual General Meeting
2022-09-23Annual General Meeting
DateTypeWhat it says
2026-10-01Shareholder meetingVoting results.
2026-09-30Shareholder meetingProceedings of Annual General Meeting held on September 30, 2026
2026-09-08ResignationResignation of Director/KMP/SMP
2026-09-08Shareholder meetingNotice of Annual General Meeting to be held on September 30, 2026
2026-09-07Director changeChange in Director(s) of the company.
2026-09-07Board meeting outcomeOutcome of Board Meeting held on September 07, 2026.
2026-08-14Board meeting outcomeORTIN GLOBAL LIMITED has submitted to the Exchange, the financial results for the period ended Jun 30, 2026.
2026-07-13UpdatesRarever Financial Advisors Private Limited has submitted to  the Exchange a copy of Post-offer advertisement under Regulation 18(12) in terms  of the ...
2026-07-09Reply to Clarification- FinaThe Exchange had sought clarification from ORTIN GLOBAL LIMITED for the quarter ended 31-Mar-2026 with respect to Regulation 33 of the SEBI (Listing O...
2026-06-27Clarification - Financial ReThe Exchange has sought clarification from ORTIN GLOBAL LIMITED for the quarter ended 31-Mar-2026 with respect to Regulation 33 of the SEBI (Listing O...
2026-06-15Disclosure under SEBI TakeovS. Murali Krishna Murthy has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Subs...
2026-06-12Disclosure under SEBI TakeovS. Murali Krishna Murthy has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) and 31 (5) of the Securities and Exchange Board of ...
2026-06-05UpdatesRarever Financial Advisors Private Limited has submitted to  the Exchange a copy of Pre-offer advertisement cum corrigendum of the public announcement...
2026-06-05UpdatesRarever Financial Advisors Pvt. Ltd. (Manager to the Offer) has submitted to the Exchange a copy of Recommendations of the Committee of Independent Di...
2026-05-30Board meeting outcomeORTIN GLOBAL LIMITED has submitted to the Exchange, the financial results for the period ended March 31, 2026.
2026-05-06UpdatesReporting of Initial Disclosure to Be Made by an entity identified as a LargeCorporate.
2026-04-30UpdatesReporting of Annual Disclosure to be made by an entity identified as a Large Corporate.
2026-02-26CorrigendumRarever Financial Advisors Pvt. Ltd. (Manager to the Offer) has submitted to the Exchange a copy of Corrigendum to the detailed public statement for t...
2026-02-18Public Announcement-Open OffRarever Financial Advisors Pvt. Ltd. (Manager to the Offer) has submitted to the Exchange a copy of Detailed Public Statement in terms of Regulation 4...
2026-02-16UpdatesRarever Financial Advisors Pvt. Ltd. has submitted to the Exchange a copy of Corrigendum Public Announcement to the Shareholders of Ortin Global Limit...
2026-02-14Board meeting outcomeORTIN GLOBAL LIMITED has submitted to the Exchange, the financial results for the period ended December 31, 2025.
2026-02-14Integrated Filing- FinancialUn-audited financial results along with the Limited Review Report as per Regulation 33 of SEBI(LODR) Regulations, 2015, for the quarter ended 31.12.20...
2026-02-11Open OfferRarever Financial Advisors Pvt. Ltd. has submitted to the Exchange a copy of Public Announcement to the Shareholders of Ortin Global Limited ( Target ...
2025-11-14Board meeting outcomeResults for the quarter and half year ended 30.09.2025
Company filings to NSE, newest first. Routine notices (trading window, newspaper copies) are left out. Click a row for the filing.
No short selling reported to NSE in our files.
Short sales disclosed by brokers to NSE, by trade date. Collected since late September 2026.
Order dateForumCase
2020-10-09NCLTOrtin Laboratories Ltd & Vineet Laboratories Ltd Vs
2020-09-07NCLTOrtin Laboratories Ltd & Vineet Laboratories Ltd Vs
2020-08-26NCLTOrtin Laboratories Ltd & Vineet Laboratories Ltd Vs
Orders from NCLT, NCLAT and CESTAT naming the company. Click a row for the order.
EPS in the scrip is zero (4 trailing quarters)GSMLess than 100 unique PAN traded in previous 30 daysLoss making
Data: NSE and BSE daily reports, company filings. Numbers only, not investment advice, not a SEBI-registered research service.Updated 2026-10-03